GenMont Biotech (TPE:3164) PE Ratio without NRI: 24.92 (As of Jul. 08, 2026) — 15% Below Median


TPE:3164 GenMont Biotech Inc TPE:3164
82 GF Score
Price NT$16.55
GF Value NT$26.24
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GenMont Biotech PE Ratio without NRI?

GenMont Biotech TPE:3164 +0.30% 82 PE Ratio without NRI is 24.92 as of Jul. 08, 2026, which is 15% below its 10-year median of 29.32. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 265 Biotechnology companies, GenMont Biotech ranks better than 50.57% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-08), GenMont Biotech's share price is NT$16.55. GenMont Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.66. Therefore, GenMont Biotech's PE Ratio without NRI for today is 24.92.

During the past 13 years, GenMont Biotech's highest PE Ratio without NRI was 108.67. The lowest was 16.73. And the median was 29.32.

GenMont Biotech's EPS without NRI for the three months ended in Dec. 2025 was NT$0.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.66.

As of today (2026-07-08), GenMont Biotech's share price is NT$16.55. GenMont Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.66. Therefore, GenMont Biotech's PE Ratio (TTM) for today is 25.08.

Good Sign:

GenMont Biotech Inc stock PE Ratio (=24.7) is close to 3-year low of 24.09.

During the past years, GenMont Biotech's highest PE Ratio (TTM) was 118.33. The lowest was 11.85. And the median was 30.76.

GenMont Biotech's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.66.

GenMont Biotech's EPS (Basic) for the three months ended in Dec. 2025 was NT$0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.66.


GenMont Biotech  (TPE:3164) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


GenMont Biotech PE Ratio without NRI Related Terms


GenMont Biotech PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech PE Ratio without NRI Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.31 36.74 63.82 30.79 27.55

GenMont Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.79 43.16 104.08 49.23 27.55

TPE:3164 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, GenMont Biotech's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMont Biotech PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenMont Biotech's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where GenMont Biotech's PE Ratio without NRI falls into.


TPE:3164
82GF Score
GenMont Biotech Inc TPE:3164
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

GenMont Biotech's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=16.55/0.664
=24.92

GenMont Biotech's Share Price of today is NT$16.55.
GenMont Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.66.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 24.92 mean?
GenMont Biotech (TPE:3164) has a PE Ratio without NRI of 24.92 as of Jul. 08, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on GenMont Biotech and its competitors. This is 15% below median its historical median of 29.32. Over the past decade, GenMont Biotech's PE Ratio without NRI has ranged from 16.73 to 108.67. According to the industry distribution chart, GenMont Biotech ranks #131 out of 265 companies in the Biotechnology industry, placing it in the top 49.4%.
Is GenMont Biotech's PE Ratio without NRI too high?
GenMont Biotech's current PE Ratio without NRI of 24.92 is 15% below median its 10-year median of 29.32. Over the past 10 years, this metric has ranged from a low of 16.73 to a high of 108.67. The Biotechnology industry median PE Ratio without NRI is 25.30. GenMont Biotech's value of 24.92 is 1.5% below this industry median. Based on the distribution chart, GenMont Biotech ranks #131 out of 265 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #131 out of 265 companies for PE Ratio without NRI. This puts GenMont Biotech in the upper half of its industry. The industry median PE Ratio without NRI is 25.30. GenMont Biotech's value of 24.92 is 1.5% below this benchmark. Historically, GenMont Biotech's own PE Ratio without NRI has ranged from 16.73 to 108.67 over the past decade. While the company's 10-year median is 29.32 vs. the industry median of 25.30, GenMont Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.30, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current PE Ratio without NRI of 24.92 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on GenMont Biotech and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current PE Ratio without NRI is 24.92, which is 15% below median its own 10-year median of 29.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current PE Ratio without NRI is 24.92, which is 15% below median its 10-year median of 29.32 and 1.5% below the Biotechnology industry median of 25.30. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current PE Ratio without NRI is 24.92 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24. GuruFocus considers GenMont Biotech to be Significantly Undervalued.

Key valuation signals for TPE:3164:

  • PE Ratio without NRI: 24.92 (15% below median its 10-year median of 29.32)
  • GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
  • GF Score™: 82/100 with 5 warning signs
  • Industry Position: 1.5% below the Biotechnology median (#131 of 265)

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score

Get the complete analysis for TPE:3164

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.55
Price
NT$26.24
GF Value